Establishing an infrastructure for
self-administered blood tests
The healfh care industry is changing, it will become proactive and customized. This Change is based on data, on proactiveness in data collection. Tiselia infrastructure for self-administered blood tests is crucial for proactive data collection.
Tiselia intends to Transform lab services by productize it. Putting these in the hands of patients and consumers for self-testing and thus to enable improved healthcare. Tiselia’s Solution are Cost-effective, Rapid and painless, Sensitive and accurate. Tiselia enable data flow so it can be used for prediction and for creating actionable panels.
US clinical laboratory services market is ~$53B annually, with a CAGR of 6.2% through 2020. $24.1B is independent and 50% of which is controlled by Quest and LabCorp. While market only accounts for 2-3% of all healthcare costs, it impacts 70-80% of physicians’ decisions. Quest and Labcorp have COGS of ~62% of revenues, mainly due to their extensive logistics operation.
Tiselia will initially focus on the 26 most common tests ($6B revenues), more than 500M annual tests. Tiselia will lower prices of individual blood tests by at least 60-70% Although frequent testing will increase volumes. Overall blood test revenues will decrease, but less than the price drop.
Tiselia first offering will be directed at patients with Congestive Heart Failure (CHF). CHF Patients tend to be very sick, with numerous comorbidities, they tend to have limited mobility and frequently need medical attention from all caregivers (physicians, nurses, hospitals and others). Only 50.4% survive 5-year and 14.7% survive up to 10-year . Polypharmacy approaches require tight monitoring (diuretics, vasodilators, and neurohormonal Antagonists) the patients are so severely ill.
Now let's talk numbers.
CHF is Prevalent in 5.7 million Americans and every year 550K new patients diagnosed. The direct costs claimed on those patients estimated as $60B (Voigt et al 2014). 1-4% of all are hospitalizations, 1.1 M hospitalizations for 1 st HF, and 4M hospitalizations associated with HF. 19%-25% are readmission in 30 days from last admission. The FDA has approved cardioMEMS, a $20,000 implantable device aimed at preventing hospital admission.
Guideline Directed Medical Treatment (GDMT) for heart failure involves frequent change of treatment and dosing adjustments Home blood testing will allow compliance with treatment guidelines, removing cost and patient inconvenience barriers But, GDMT is difficult to comply with for physician and patient, because it requires frequent monitoring of renal function and potassium levels GDMT has been shown to reduce decompensations and thus to reduce hospitalization, rehospitalizations, morbidity and mortality
Tiselia solution will be integrated to care systems to establish a routine of home-testing for distributed diagnostics. By so the care systems will Decrease the use of emergency room, Improve their cost-efficient telemedicine offer , Decrease hospital admissions and Enable to offer more frequent monitoring . This will improve patient outcome and patient quality of life
Let’s get specific
Tiselia platform will cover additional disease-oriented panels, to include most actionable indications. We believe in empowering telemedicine by leveling the playfield between hospital-based care and remote care. Our infrastructure will promote frequent testing, predictive and precision medicine, learning-assisted decision making and novel content development.
The solution is based On-chip reaction that enables super-concentration of target analytes –by orders of magnitude. Super concentration analyses reduce the required sample volume, speed up the assay time and improve level of detection. The technology is based on intellectual property of the Technion and Harvard: 12 patent applications at the Us and Europe and 2 US patents.
Tiselia technology was publish in leading peer reviewed journal: Advanced Materials, Lab on a Chip, analytical chemistry.
Tiselia an Israeli digital health company established in 2016. Developing home- based blood diagnostics.